FIELD: biotechnology.
SUBSTANCE: invention is related to a method for inducing breast cancer resistance protein (BCRP, ABCG2) in an experiment on a human hepatocellular carcinoma cell line HepG2 by culturing human cells in Dulbecco's modified Eagle's medium containing glucose, bovine serum, penicillin and streptomycin until a monolayer is formed, followed by the addition of progesterone to the culture medium until its concentration reaches 10 and 100 mcM and incubation for 24 hours.
EFFECT: invention makes it possible to develop an accessible method for increasing the amount of breast cancer resistance protein in an experiment on a human hepatocellular carcinoma cell line HepG2.
1 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INCREASING AMOUNT OF POLYPEPTIDE TRANSPORTING ORGANIC ANIONS 1B1 (OATP1B1) | 2024 |
|
RU2823925C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| HUMAN BREAST CANCER CELL LINE BrCCh4e | 2019 |
|
RU2717654C1 |
| METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| METHOD FOR SELECTING THERAPEUTIC APPROACH IN PATIENTS WITH SCHIZOPHRENIA | 2022 |
|
RU2821045C1 |
| METHOD FOR INHIBITION OF GLYCOPROTEIN-P IN AN IN VITRO EXPERIMENT | 2021 |
|
RU2779177C1 |
| ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| METHOD OF ABCB1 PROTEIN INHIBITION IN EXPERIMENT IN VITRO | 2023 |
|
RU2811993C1 |
